Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
87.53 BRL | +8.46% | +0.13% | +40.12% |
05:28pm | NOVO NORDISK : JP Morgan reiterates its Buy rating | ZD |
03:19pm | Novo Nordisk's Ozempic Reduces Kidney Disease, Death Risk According to Study of Patients With Type 2 Diabetes | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.36 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+40.12% | 603B | - | ||
+38.79% | 728B | C+ | ||
-5.20% | 360B | C+ | ||
+19.85% | 332B | B- | ||
+1.76% | 279B | C+ | ||
+16.17% | 244B | B+ | ||
+8.07% | 207B | B- | ||
-5.69% | 205B | A+ | ||
+6.36% | 164B | C+ | ||
-0.08% | 122B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVO B Stock
- N1VO34 Stock
- Ratings Novo Nordisk A/S